Login | New Member? Signup Free
ChangeDetect » News

SLN to present Atu027 Phase I study data against solid cancer at ASCO Annual Meeting

Silence Therapeutics plc a leading global RNA interference therapeutics company, announces that interim data from its ongoing Phase I clinical study of Atu027, the Company’s lead internal therapeutic candidate, have been accepted for poster presentation at the 2011 American Society of Clinical Oncology Annual Meeting. (3 hours ago)

Tags: , , , , , , , ,

Sessions at the AVA Annual Scientific Meeting to Explore Patient Safety and Proven Prevention Strategies for

BLOOMINGTON, Ind.—-At AVA’s 24th Annual Meeting, Cook Medical will sponsor two sessions that examine how to combine process and technology to reduce the risk of dangerous catheter-related bloodstream infections. (8 hours ago)

Tags: , , , , , , , , ,